Risk factors
Xenon Pharmaceuticals (XENE) risk factors
Item 1A of every Xenon Pharmaceuticals Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors85 risks4 new1 dropped20 reworded
Xenon faces new operational and commercial risks as it advances its lead candidate, azetukalner, into Phase 3 clinical trials for epilepsy, major depressive disorder, and bipolar depression.
Filed Feb 26, 2026 - FY2024 10-K risk factors82 risks
Biopharmaceutical development risks dominate, focusing on clinical trial success for azetukalner, regulatory approvals by FDA and EMA, and financing needs.
Filed Feb 27, 2025